Evrofarma SA

ATSE:EVROF Stock Report

Market Cap: €26.3m

Evrofarma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Evrofarma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Food earnings growth10.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price

Dec 19
A Piece Of The Puzzle Missing From Evrofarma SA's (ATH:EVROF) Share Price

Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Oct 02
Earnings Troubles May Signal Larger Issues for Evrofarma (ATH:EVROF) Shareholders

Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Feb 29
Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Jan 06
Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Jan 05
Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Dec 01
Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Sep 15
Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Is Evrofarma (ATH:EVROF) Using Too Much Debt?

May 27
Is Evrofarma (ATH:EVROF) Using Too Much Debt?

We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Oct 04
We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

May 19
Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Feb 22
Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Dec 29
Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

Nov 22
Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Evrofarma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ATSE:EVROF - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202447225N/A
3/31/202448214N/A
12/31/202349213N/A
9/30/202349313N/A
6/30/202349313N/A
3/31/202347213N/A
12/31/202245113N/A
9/30/2022420-11N/A
6/30/202239-1-30N/A
3/31/202238-1-40N/A
12/31/2021370-4-1N/A
9/30/2021361-3-1N/A
6/30/2021361-2-1N/A
3/31/2021351-10N/A
12/31/202034111N/A
9/30/202033112N/A
6/30/202032022N/A
3/31/202033012N/A
12/31/201933012N/A
9/30/201934001N/A
6/30/201935101N/A
3/31/201934112N/A
12/31/201833112N/A
9/30/201832123N/A
6/30/201831123N/A
3/31/2018311N/A3N/A
12/31/2017311N/A3N/A
9/30/2017310N/A3N/A
6/30/2017300N/A3N/A
3/31/2017300N/A2N/A
12/31/2016290N/A1N/A
9/30/2016280N/A0N/A
6/30/2016280N/A1N/A
3/31/2016300N/A1N/A
12/31/2015301N/A1N/A
9/30/2015290N/A2N/A
6/30/2015280N/A2N/A
3/31/2015260N/A1N/A
12/31/2014250N/A1N/A
9/30/2014250N/A0N/A
6/30/2014250N/A0N/A
3/31/2014240N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if EVROF's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if EVROF's earnings are forecast to grow faster than the Greek market

High Growth Earnings: Insufficient data to determine if EVROF's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if EVROF's revenue is forecast to grow faster than the Greek market.

High Growth Revenue: Insufficient data to determine if EVROF's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EVROF's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 07:25
End of Day Share Price 2025/01/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evrofarma SA is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution